Prognostic factors in early-stage ovarian cancer

ecancermedicalscience

Volumn 7, Issue 1, 2013, Pages

  Tognon, Germana ^a   Carnazza, Mario ^a   Ragnoli, Monica ^a   Calza, Stefano ^a,b   Ferrari, Federico ^a   Gambino, Angela ^a   Zizioli, Valentina ^a   Notaro, Sara ^a   Sostegni, Benedetta ^a   Sartori, Enrico ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adjuvant chemotherapy; Conservative treatment; Dense adhesions; Early stage ovarian cancer; Peritoneal cytology; Prognostic factors; Taxanes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONSERVATIVE TREATMENT; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; OVARY CANCER; PREOPERATIVE PERIOD; TREATMENT DURATION;

EID: 84879658780     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2013.325     Document Type: Article

References (48)

1. Dembo AJ et al (1990) Prognostic factors in patients with stage I epithelial ovarian cancer Obstet Gynecol 263-73 PMID: 2300355 (Pubitemid 20062245)
2. Vergote I et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma Lancet 357 176-82 DOI: 10.1016/S0140-6736(00)03590-X PMID: 11213094 (Pubitemid 32108089)
3. Smedley H et al (1985) Age as a prognostic factor in epithelial ovarian cancer Int J Obstet Gynecol 839-42 PMID: 4027207 (Pubitemid 16172055)
4. Thigpen T et al (1993) Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group Experience Cancer 71 606-14 DOI: 10.1002/cncr.2820710218
5. Duska LR et al (1999) Epithelial ovarian carcinoma in the reproductive age group Cancer 85(18) 623-9 DOI: 10.1002/(SICI)1097-0142(19990615)85: 12〈;26232623::AID-CNCR19〉;3.0.CO;2-O
6. Chan JK et al (2008) Prognostic factors for high-risk early-stage epithelial ovarian cancer. A Gynecologic Oncology Group Study Am Cancer Society 112 2202-10 DOI: 10.1002/cncr.23390 PMID: 18348296
7. Ahmed FY (1996) Natural history and prognosis of untreated stage I epithelial ovarian cancer J Clin Oncol 14 2968-75 PMID: 8918494
8. Sevelda P (1989) CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer Am J Obstet Gynecol 161 1213-6 DOI: 10.1016/0002-9378(89)90668-6 PMID: 2589442
9. Makar AP (1992) Prognostic value of pre- and post-operative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis Obstet Gynecol 72 1002-10 PMID: 1579296
10. Osman N (2008) Correlation of serum CA 125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre Ir J Med 101 245-7 PMID: 18990955
11. Buller RE et al (1996) CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s Am J Obstet Gynecol 174 1241-53 DOI: 10.1016/S0002-9378(96)70667-1 PMID: 8623852
12. Zanetta G and Rota S (1998) The accuracy of staging : an important prognostic determinator in stage I ovarian carcinoma Ann Oncol 9 1097-101 DOI: 10.1023/A:1008424527668 PMID: 9834822 (Pubitemid 28518148)
13. Zanetta G (1997) Conservative surgery for stage I ovarian carcinoma in women of childbearing age Br J Obstet Gynecol 104 1030-5 DOI: 10.1111/j.1471-0528.1997.tb12062.x
14. Petru E et al (1994) Lynphadenectomy in stage I ovarian cancer Am J Obstet Gynecol 170 656-62 DOI: 10.1016/S0002- 9378(94)70244-6 PMID: 8116728
15. Lang JH et al (1994) Lymph node metastasis in stage I ovarian carcinoma Chin Med 107 643-7 PMID: 7805453
16. Onda T, Yoshikawa H, et al (1996) Assessment of metastasis to aortic and pelvic lymph nodes in epithelial ovarian carcinoma Cancer 78 803-8 DOI: 10.1002/(SICI)1097-0142(19960815)78:4〈;803::AID-CNCR17〉;3.0.CO;2-Z PMID: 8756375
17. Colombo N et al (2003) International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early stage ovarian cancer J Natl Cancer Inst 125-32 PMID: 12529345 (Pubitemid 36193261)
18. Trimbos JB, Vergote I, Bolis G et al (2003) Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. For the EORTC-ACTION collaborators J Natl Cancer Inst 113-25 DOI: 10.1093/jnci/95.2.113
19. Mc Guire WP (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III/IV ovarian cancer N Engl J Med 334 1-6 DOI: 10.1056/NEJM199601043340101
20. Piccart MJ et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year result J Nat Cancer 92 699-708 DOI: 10.1093/jnci/92.9.699
21. Bolis G et al (1995) Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P) Ann Oncol 6 887-93 PMID: 8624291
22. Trope C et al (2000) Randomized study on adjuvant chemotherapy in stage I high risk ovarian cancer with evaluation of DNA ploidy as prognostic instrument Ann Oncol 11 281-8 DOI: 10.1023/A:1008399414923 (Pubitemid 30214664)
23. Suzuki M et al (2000) Lymph node metastasis in stage I epithelial ovarian cancer Gynecol Oncol 79 305-8 DOI: 10.1006/gyno.2000.5951 PMID: 11063662
24. Vergote IB et al (1993) Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse Am J Obstet Gynecol 169 40-52 DOI: 10.1016/0002-9378(93)90129-7 PMID: 8333474 (Pubitemid 23223926)
25. Bertelsen K et al (1993) Prognostic factors and adjuvant treatment in early epithelial ovarian cancer Int J Gynecol Cancer 4 211-18 PMID: 11578348 (Pubitemid 23361859)
26. Maiman M et al (1991) Laparoscopic excision of ovarian neoplasms subsequently found to be malignant Obstet Gynecol 77 563-65 PMID: 1825866
27. Leminen A et al (1999) Spread of ovarian cancer after laparoscopic surgery: report of eight cases Gynecol Oncol 75 387-90 DOI: 10.1006/gyno.1999. 5596 PMID: 10600294
28. Lehner R et al (1998) Influence of delayed staging laparotomy after laparoscopic removal of varian masses later found malignant Obstet Gynecol 92 967-71 DOI: 10.1016/S0029-7844(98)00323-8 PMID: 9840559 (Pubitemid 28536112)
29. Trimbos JB et al (1991) Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer Cancer 67 597-602 DOI: 10.1002/1097-0142(19910201)67:3〈;597::AID-CNCR2820670313〉;3.0.CO;2-A PMID: 1985754
30. Schueler JA et al (1993) Prognostic factors in well-differentiated early-stage ovarian cancer Cancer 71(3) 787-95 DOI: 10.1002/1097-0142(19930201) 71:3〈;787::AID-CNCR2820710322〉;3.0.CO;2-2 PMID: 8431861 (Pubitemid 23051383)
31. Rubin SC et al (1993) Platinum based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging Obstet Gynecol 82 143-7 PMID: 8515915 (Pubitemid 23200559)
32. Ingirídur Skírnisdóttir and Tomas Seidal (2011) Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer Int J Gynecol Cancer 21(6) 1024-31 DOI: 10.1097/IGC.0b013e31821dc906
33. But I et al (2000) DNA ploidy as an independent prognostic factor in patients with serous ovarian carcinoma Int J Gynecol Obstet 71(3) 259-62 DOI: 10.1016/S0020-7292(00)00277-0
34. Schueler JA et al (1999) DNA index reflects the biological behaviour of ovarian carcinoma stage I-IIA Gynecol Oncol 62 59-66 DOI: 10.1006/gyno.1996.0190
35. Wagner TM (1994) Prognostic importance of cell-DNA content in early stage ovarian cancer (FIGO stage I-IIA) by means of automatic image cytometry Int J Cancer 56(2) 167-72 DOI: 10.1002/ijc.2910560203 PMID: 8314296
36. Brugghe J et al (1998) Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment Gynecol Oncol 68(1) 47-53 DOI: 10.1006/gyno.1997.4884 PMID: 9454660 (Pubitemid 28109823)
37. Onder T et al (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways Cancer Res 68 3645 DOI: 10.1158/0008-5472. CAN-07-2938 PMID: 18483246
38. Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers Am J Pathol 153(2) 333-9 DOI: 10.1016/S0002-9440(10) 65575-7 PMID: 9708792
39. Abercrombie M and Ambrose EJ (1962) The surface properties of cancer cells: a review Cancer Res 22 525-48 PMID: 13858936
40. Ambrose EJ and Ellison M (1968) Studies of specific properties of tumour cell membranes using stereoscan microscopy Eur J Cancer 4(5) 459-62 PMID: 5760728
41. Ambrose EJ, James AM, and Lowich JHB (1956) Differences between the electrical charge carries by normal and homologous tumour cells Nature 177 576-7 DOI: 10.1038/177576a0 PMID: 13321908
42. Shankaran V et al (2001) IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 1107-11 DOI: 10.1038/35074122 PMID: 11323675 (Pubitemid 32391043)
43. de Visser KE et al (2006) Paradoxical roles of the immune system during cancer development Cancer 6 24-37 PMID: 16397525
44. Ginaldi L et al (1999) The immune system in the elderly Immun Res 20(2) 101-26
45. Lengyel E (2010) Ovarian cancer development and metastasis Am J Pathol 177(3) 1053-64 DOI: 10.2353/ajpath.2010.100105 PMID: 20651229 PMCID: 2928939
46. Decker DG et al (1982) Cyclophosphamide plus cis-platinum in combination: treatment program for stage III and IV ovarian carcinoma Obstet Gynecol 60(4) 481-7 PMID: 6889714 (Pubitemid 12018878)
47. ACOG committee opinion (1996) Second-look laparotomy for sp ovarian cancer Committee on Gynecologic Practice Int J Gynecol Obstet 53(1) 81-3
48. Escobar PF, Michener CM and Rose PG (2005) Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer Int J Gynecol Cancer Nov-Dec; 15(6) 1258; author reply 1259. No abstract available. PMID: 16343227